Dilept: defined peptide-derived formulation — RU2420304C2
Сергей Борисович Середенин (RU), Сергей Борисович Середенин, Борис Михайлович Пятин (RU), Борис Михайлович Пятин, Нина Ивановна Авдюнина (RU), Нина Ивановна Авдюнина, Константин Викторович Алексеев (RU), Константин Викторович Алексеев, Любовь Николаевна Грушевская (RU), Любовь Николаевна Грушевская, Евгения Викторовна Блынская (RU), Евгения Викторовна Блынская, Раиса Филипповна Большакова (RU), Раиса Филипповна Большакова, Максим Владимирович Гусев (RU), Максим Владимирович Гусев, Ольга Михайловна Шендера (RU), Ольга Михайловна Шендера · 2011 · RU2420304C2 · patent family 42685698
Published 2011-06-10.
Reported patent results
Narrative findings; numerical extraction incomplete
The patent reports producing solid dosage forms that meet stated quality requirements.
Dilept formulation/process examples and pharmacopoeial quality specifications; no clinical antipsychotic comparison.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Formulation outcome | Example tablets/capsules are reported to meet pharmacopoeial requirements | A manufacturing claim supported by preparation examples, not a clinical response |
| Quality specifications | Capsule disintegration limit ≤20 minutes; impurity limits ≤0.5% individually and ≤1% total | These are acceptance limits, not measured patient outcomes or observed batch values |
The specification table must not be mistaken for a clinical results table or evidence of antipsychotic efficacy. Actual batch measurements are not independently extracted here.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Formulation. The patent identifies a formulation involving N-caproyl-L-prolyl-L-tyrosine methyl ester.
Exact chemical identity matters; the formulation patent does not establish comparative antipsychotic efficacy.
- Publication
- RU2420304C2 ↗ · 2011-06-10
- Earliest priority / filing
- 2009-01-15 / 2009-01-15
- Original applicant / assignee
- Учреждение Российской Академии Медицинских Наук Научно-Исследовательский Институт Фармакологии Имени В.В.Закусова Рамн
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 42685698 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Pharmaceutical composition with antipsychotic action
Inventors: Сергей Борисович Середенин (RU); Сергей Борисович Середенин; Борис Михайлович Пятин (RU); Борис Михайлович Пятин; Нина Ивановна Авдюнина (RU); Нина Ивановна Авдюнина; Константин Викторович Алексеев (RU); Константин Викторович Алексеев; Любовь Николаевна Грушевская (RU); Любовь Николаевна Грушевская; Евгения Викторовна Блынская (RU); Евгения Викторовна Блынская; Раиса Филипповна Большакова (RU); Раиса Филипповна Большакова; Максим Владимирович Гусев (RU); Максим Владимирович Гусев; Ольга Михайловна Шендера (RU); Ольга Михайловна Шендера.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Exact chemical identity matters; the formulation patent does not establish comparative antipsychotic efficacy.
- The specification table must not be mistaken for a clinical results table or evidence of antipsychotic efficacy. Actual batch measurements are not independently extracted here.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-42685698. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: Сергей Борисович Середенин (RU), Сергей Борисович Середенин, Борис Михайлович Пятин (RU), Борис Михайлович Пятин, Нина Ивановна Авдюнина (RU), Нина Ивановна Авдюнина, Константин Викторович Алексеев (RU), Константин Викторович Алексеев, Любовь Николаевна Грушевская (RU), Любовь Николаевна Грушевская, Евгения Викторовна Блынская (RU), Евгения Викторовна Блынская, Раиса Филипповна Большакова (RU), Раиса Филипповна Большакова, Максим Владимирович Гусев (RU), Максим Владимирович Гусев, Ольга Михайловна Шендера (RU), Ольга Михайловна Шендера. Dilept: defined peptide-derived formulation — RU2420304C2 RU2420304C2 · patent family 42685698 2011.
Molekul research summary: https://molekul.io/research/patent-ru2420304c2. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry